Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity
Open accessThe DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Abstract
Metabolic disorders, including obesity, diabetes, and cardiovascular disease, are widespread in Westernized nations. Gut microbiota composition is a contributing factor to the susceptibility of an individual to the development of these disorders; therefore, altering a person's microbiota may ameliorate disease. One potential microbiome-altering strategy is the incorporation of modified bacteria that express therapeutic factors into the gut microbiota. For example, N-acylphosphatidylethanolamines (NAPEs) are precursors to the N-acylethanolamide (NAE) family of lipids, which are synthesized in the small intestine in response to feeding and reduce food intake and obesity. Here, we demonstrated that administration of engineered NAPE-expressing E. coli Nissle 1917 bacteria in drinking water for 8 weeks reduced the levels of obesity in mice fed a high-fat diet. Mice that received modified bacteria had dramatically lower food intake, adiposity, insulin resistance, and hepatosteatosis compared with mice receiving standard water or control bacteria. The protective effects conferred by NAPE-expressing bacteria persisted for at least 4 weeks after their removal from the drinking water. Moreover, administration of NAPE-expressing bacteria to TallyHo mice, a polygenic mouse model of obesity, inhibited weight gain. Our results demonstrate that incorporation of appropriately modified bacteria into the gut microbiota has potential as an effective strategy to inhibit the development of metabolic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While human and animal studies have established the ability to successfully populate the oral cavity or gastrointestinal tract with specific strains, combinations of bacteria, or bacteria genetically modified to produce enzymes or metabolites[74,404–407]”
From Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health (2017) · cites this paper as [406]
Experimental — accuracy not yet measuredIn the citing paper
“Chen et al. demonstrated that an N-acylphosphatidylethanolamine (NAPE)-producing strain of EcN could significantly ameliorate symptoms associated with high-fat diet feeding in mice. Mice treated with this recombinant EcN displayed reduced adiposity, insulin resistance, and hepatosteatosis compared to animals treated with an unengineered EcN control37.”
From Developing a new class of engineered live bacterial therapeutics to treat human diseases (2020) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB
DeSantis, T. Z., Hugenholtz, P., Larsen, N., Rojas, M., Brodie, E. L., Keller, K., Huber, T., Dalevi, D., Hu, P., & Andersen, G. L. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.03006-05 · Cited by 10,891
Human gut microbes associated with obesity
Ley, R. E., Turnbaugh, P. J., Klein, S., & Gordon, J. I. (2006) · Nature · doi:10.1038/4441022a · Cited by 8,785
A core gut microbiome in obese and lean twins
Turnbaugh, P. J., Hamady, M., Yatsunenko, T., Cantarel, B. L., Duncan, A., Ley, R. E., Sogin, M. L., Jones, W. J., Roe, B. A., Affourtit, J. P., et al. (2009) · Nature · doi:10.1038/nature07540 · Cited by 7,823
Prevalence and Trends in Obesity Among US Adults, 1999-2008
Flegal, K. M. (2010) · JAMA · doi:10.1001/jama.2009.2014 · Cited by 7,580 · cited 1×
“org Volume 124 Number 8 August 2014 Introduction Obesity dramatically increases the risks for cardiovascular disease and diabetes as well as other diseases, and rates of obesity have increased dramatically in the past 25 years (1, 2).”
Obesity alters gut microbial ecology
Ley, R. E., Bäckhed, F., Turnbaugh, P., Lozupone, C. A., Knight, R. D., & Gordon, J. I. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504978102 · Cited by 6,176 · cited 1×
“Changes in global gut microbiota, including an increased ratio of Firmicutes to Bacteroidetes, have been associated with obesity (9, 36–38).”
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597
Cani, P. D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A. M., Delzenne, N. M., & Burcelin, R. (2008) · Diabetes · doi:10.2337/db07-1403 · Cited by 4,819
Congenital leptin deficiency is associated with severe early-onset obesity in humans
Montague, C. T., Farooqi, I. S., Whitehead, J. P., Soos, M. A., Rau, H., Wareham, N. J., Sewter, C. P., Digby, J. E., Mohammed, S. N., Hurst, J. A., et al. (1997) · Nature · doi:10.1038/43185 · Cited by 2,936 · cited 1×
“However, mutations in these genes are rare in humans and cause extreme forms of obesity (39–41).”
Turnbaugh, P. J., Bäckhed, F., Fulton, L., & Gordon, J. I. (2008) · Cell Host & Microbe · doi:10.1016/j.chom.2008.02.015 · Cited by 2,915
Research works printed but not linked: 3
- Kramer, 1989, Int J Obes., 13, 123
- Wadden, 1989, Int J Obes., 13, 39
- Harris, 2012, J Obes., 2012, 879151
Cited by
The Human Intestinal Microbiome in Health and Disease
Lynch, S. V., & Pedersen, O. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1600266 · Cited by 3,637
Gut microbiota in cardiovascular health and disease
Tang, W. H. W., Kitai, T., & Hazen, S. L. (2017) · Circulation Research · doi:10.1161/circresaha.117.309715 · Cited by 1,670
Impacts of gut bacteria on human health and diseases
Zhang, Y.-J., Li, S., Gan, R.-Y., Zhou, T., Xu, D.-P., & Li, H.-B. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16047493 · Cited by 1,055
Self-citationThe host shapes the gut microbiota via fecal microRNA
Liu, S., da Cunha, A. P., Rezende, R. M., Cialic, R., Wei, Z., Bry, L., Comstock, L. E., Gandhi, R., & Weiner, H. L. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2015.12.005 · Cited by 808
“, 2011) and metabolism (Chen et al., 2014), including SFB, E.”
Isabella, V. M., Ha, B. N., Castillo, M. J., Lubkowicz, D. J., Rowe, S. E., Millet, Y. A., Anderson, C. L., Li, N., Fisher, A. B., West, K. A., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4222 · Cited by 605
Microbial regulation of organismal energy homeostasis
Cani, P. D., Van Hul, M., Lefort, C., Depommier, C., Rastelli, M., & Everard, A. (2019) · Nature Metabolism · doi:10.1038/s42255-018-0017-4 · Cited by 569
Microbiome, probiotics and neurodegenerative diseases: deciphering the gut brain axis
Westfall, S., Lomis, N., Kahouli, I., Dia, S. Y., Singh, S. P., & Prakash, S. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2550-9 · Cited by 541
Developing a new class of engineered live bacterial therapeutics to treat human diseases
Charbonneau, M. R., Isabella, V. M., Li, N., & Kurtz, C. B. (2020) · Nature Communications · doi:10.1038/s41467-020-15508-1 · Cited by 523
Lagkouvardos, I., Joseph, D., Kapfhammer, M., Giritli, S., Horn, M., Haller, D., & Clavel, T. (2016) · Scientific Reports · doi:10.1038/srep33721 · Cited by 506
“The next highest abundances (ca. 4% total reads) originated also from a mouse model of diet-induced obesity 24 .”
Zhang, L. S., & Davies, S. S. (2016) · Genome Medicine · doi:10.1186/s13073-016-0296-x · Cited by 500
“AhR: aryl hydrocarbon receptor; AMPK: AMP kinase; CKD: chronic kidney disease; CLA: conjugated linoleic acid; CLnA: conjugated linolenic acid; CoA: coenzyme A; CVD: cardiovascular disease; DMB: 3,3-dimethyl-1-butanol; DSS: dextran sodium sulfate; EPS: 4-ethylphenylsulfate; GIP: gastric inhibitory polypeptide; GLP: glu…”
BackgroundInfluentialSelf-citationCommensal bacteria make GPCR ligands that mimic human signalling molecules
Cohen, L. J., Esterhazy, D., Kim, S.-H., Lemetre, C., Aguilar, R. R., Gordon, E. A., Pickard, A. J., Cross, J. R., Emiliano, A. B., Han, S. M., et al. (2017) · Nature · doi:10.1038/nature23874 · Cited by 500
Poroyko, V. A., Carreras, A., Khalyfa, A., Khalyfa, A. A., Leone, V., Peris, E., Almendros, I., Gileles-Hillel, A., Qiao, Z., Hubert, N., et al. (2016) · Scientific Reports · doi:10.1038/srep35405 · Cited by 480
Gut microbiota: A player in aging and a target for anti-aging intervention
Vaiserman, A. M., Koliada, A. K., & Marotta, F. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.01.001 · Cited by 465
Engineering bacteria for diagnostic and therapeutic applications
Riglar, D. T., & Silver, P. A. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.172 · Cited by 460
Yehl, K., Lemire, S., Yang, A. C., Ando, H., Mimee, M., Torres, M. D. T., de la Fuente-Nunez, C., & Lu, T. K. (2019) · Cell · doi:10.1016/j.cell.2019.09.015 · Cited by 437
The Gut Microbial Endocrine Organ: Bacterially Derived Signals Driving Cardiometabolic Diseases
Brown, J. M., & Hazen, S. L. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-060513-093205 · Cited by 438
“genetically-modified strain of bacteria designed to generate high levels of a beneficial class of lipids called N-acylphosphatidylethanolamines was recently shown to protect mice from obesity-related disorders (95).”
BackgroundPostbiotics and paraprobiotics: From concepts to applications
Cuevas-González, P. F., Liceaga, A. M., & Aguilar-Toalá, J. E. (2020) · Food Research International · doi:10.1016/j.foodres.2020.109502 · Cited by 431
Role of the gut microbiota in type 2 diabetes and related diseases
Yang, G., Wei, J., Liu, P., Zhang, Q., Tian, Y., Hou, G., Meng, L., Xin, Y., & Jiang, X. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154712 · Cited by 418
Acoustic reporter genes for noninvasive imaging of microorganisms in mammalian hosts
Bourdeau, R. W., Lee-Gosselin, A., Lakshmanan, A., Farhadi, A., Kumar, S. R., Nety, S. P., & Shapiro, M. G. (2018) · Nature · doi:10.1038/nature25021 · Cited by 396
Mimee, M., Tucker, A. C., Voigt, C. A., & Lu, T. K. (2015) · Cell Systems · doi:10.1016/j.cels.2015.06.001 · Cited by 387
“In mouse models, strains of Escherichia coli were engineered to produce molecules that reduce food intake and obesity (Chen et al., 2014).”
Santoru, M. L., Piras, C., Murgia, A., Palmas, V., Camboni, T., Liggi, S., Ibba, I., Lai, M. A., Orrù, S., Blois, S., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-10034-5 · Cited by 387
Endocannabinoids–at the crossroads between the gut microbiota and host metabolism
Cani, P. D., Plovier, H., Van Hul, M., Geurts, L., Delzenne, N. M., Druart, C., & Everard, A. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.211 · Cited by 367
Brunkwall, L., & Orho-Melander, M. (2017) · Diabetologia · doi:10.1007/s00125-017-4278-3 · Cited by 355
“Further, the recombinant bacteria could be designed to respond to specific temporal signals, like dietary factors [44].”
Gut microbiota as a potential target of metabolic syndrome: the role of probiotics and prebiotics
He, M., & Shi, B. (2017) · Cell & Bioscience · doi:10.1186/s13578-017-0183-1 · Cited by 336
“demonstrated that incorporation of these modified bacteria in the drinking water of mice fed a high-fat diet resulted in dramatically lower food intake, adiposity, insulin resistance, and hepatosteatosis, whereas weight gain was inhibited in a polygenic mouse model of obesity (TallyHo mice) [36].”
Microbiome therapeutics — Advances and challenges
Mimee, M., Citorik, R. J., & Lu, T. K. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.032 · Cited by 317
Microbiota regulation of the mammalian gut-brain axis
Burokas, A., Moloney, R. D., Dinan, T. G., & Cryan, J. F. (2015) · Advances in applied microbiology · doi:10.1016/bs.aambs.2015.02.001 · Cited by 300
Manipulating Bacterial Communities by in situ Microbiome Engineering
Sheth, R. U., Cabral, V., Chen, S. P., & Wang, H. H. (2016) · Trends in Genetics · doi:10.1016/j.tig.2016.01.005 · Cited by 290
“For example, bacteria have been modified to modulate microbiota or host physiology by secreting chemicals or proteins, including human interleukin-10 to reduce inflammation [27], NAPEs to reduce food intake and obesity [28], and bacterial quorum signals to modulate microbiota composition [29].”
BackgroundGenetically stable CRISPR-based kill switches for engineered microbes
Rottinghaus, A. G., Ferreiro, A., Fishbein, S. R. S., Dantas, G., & Moon, T. S. (2022) · Nature Communications · doi:10.1038/s41467-022-28163-5 · Cited by 278
Role of the gut-brain axis in energy and glucose metabolism
Wachsmuth, H. R., Weninger, S. N., & Duca, F. A. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00677-w · Cited by 269
Abouelela, M. E., & Helmy, Y. A. (2024) · Microorganisms · doi:10.3390/microorganisms12030430 · Cited by 238
“[206] L. lactis SAGX0085 Oral and intestinal mucositis Secretes human trefoil factor 1 (hTFF1), which is believed to promote cell differentiation and limit cell proliferation and apoptosis to potentially improve the repair of oral and intestinal epithelial damage.”
BackgroundGut Microbiome and Obesity: A Plausible Explanation for Obesity
Sanmiguel, C., Gupta, A., & Mayer, E. A. (2015) · Current Obesity Reports · doi:10.1007/s13679-015-0152-0 · Cited by 204
Kain, V., Prabhu, S. D., & Halade, G. V. (2014) · Basic Research in Cardiology · doi:10.1007/s00395-014-0444-7 · Cited by 199
“Genetically engineered NAPE-expressing Escherchia coli Nissle bacteria helps to reduce murine obesity [21].”
BackgroundSzulińska, M., Łoniewski, I., Van Hemert, S., Sobieska, M., & Bogdański, P. (2018) · Nutrients · doi:10.3390/nu10060773 · Cited by 187
“The incorporation of bacteria-produced NAPEs in the drinking water of mice fed a high-fat diet for eight weeks resulted in dramatically lower food intake, adiposity, insulin resistance, and hepatosteatosis, compared with the control mice [35].”
BackgroundKoch, C. D., Gladwin, M. T., Freeman, B. A., Lundberg, J. O., Weitzberg, E., & Morris, A. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.12.015 · Cited by 186
Gut microbiota: a key player in health and disease. A review focused on obesity
Villanueva-Millán, M. J., Pérez-Matute, P., & Oteo, J. A. (2015) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-015-0390-3 · Cited by 186
“Chen et al. (2014) demonstrated that the incorporation of these modified bacteria in drinking water of a polygenic mouse model of obesity (TallyHo mice) inhibited its weight gain, while in mice fed a HFD provoked a lower food intake, adiposity, insulin resistance, and hepatosteatosis.”
BackgroundApplications of synthetic biology in medical and pharmaceutical fields
Yan, X., Liu, X., Zhao, C., & Chen, G.-Q. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01440-5 · Cited by 179
“coli was designed to treat obesity synthesizing anorexigenic lipids precursors in mice with high-fat diet.(149) Some efforts are made to degrade toxic compounds accumulated in patients via live bacteria.”
BackgroundCircadian metabolism in the light of evolution
Gerhart-Hines, Z., & Lazar, M. A. (2015) · Endocrine Reviews · doi:10.1210/er.2015-1007 · Cited by 178
Postbiotics as the new frontier in food and pharmaceutical research
Sabahi, S., Homayouni Rad, A., Aghebati-Maleki, L., Sangtarash, N., Ozma, M. A., Karimi, A., Hosseini, H., & Abbasi, A. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2056727 · Cited by 172
“Chen and colleagues, orally intake Escherichia coli Nissle 1917, which generated a specific postbiotic (Nacylphosphatidylethanolamines) and diminished obesity in mice via adjusting food consumption (Chen et al. 2014).”
Manganese promotes the aggregation and prion-like cell-to-cell exosomal transmission of α-synuclein
Harischandra, D. S., Rokad, D., Neal, M. L., Ghaisas, S., Manne, S., Sarkar, S., Panicker, N., Zenitsky, G., Jin, H., Lewis, M., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aau4543 · Cited by 172
Synthetic Biology and Engineered Live Biotherapeutics: Toward Increasing System Complexity
Ozdemir, T., Fedorec, A. J. H., Danino, T., & Barnes, C. P. (2018) · Cell Systems · doi:10.1016/j.cels.2018.06.008 · Cited by 159
Microencapsulating Alginate-Based Polymers for Probiotics Delivery Systems and Their Application
Wang, X., Gao, S.-K., Yun, S., Zhang, M., Peng, L., Li, Y., & Zhou, Y. (2022) · Pharmaceuticals · doi:10.3390/ph15050644 · Cited by 193
“In recent years, probiotics have been extensively studied as a treatment option for various diseases such as obesity [12], diabetes [13], cancer [14], human immunodeficiency virus infection [15], and irritable bowel syndrome [16] Probiotic delivery systems are critical for ensuring that a sufficient amount of probioti…”
BackgroundSong, J.-X., Ren, H., Gao, Y., Lee, C., Li, S., Zhang, F., Li, L., & Chen, H. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00602 · Cited by 166
“…modifications of the gut microbiota by dietary interventions (Xiao et al., 2014), prebiotics or probiotics (Delzenne et al., 2011), medication (Shin et al., 2014), and genetic engineering (Chen et al., 2014) are effective strategies to inhibit the development of obesity-related disorders.”
BackgroundLee, P., Yacyshyn, B. R., & Yacyshyn, M. B. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13561 · Cited by 151
“(NAPEs) are precursors to the N-acylethanolamide (NAE) family of lipids.(101) This chemical is synthesized in response to eating and acts to reduce food intake and obesity.”
BackgroundInfluentialMicrobiome therapeutics: exploring the present scenario and challenges
Yadav, M., & Chauhan, N. S. (2021) · Gastroenterology report · doi:10.1093/gastro/goab046 · Cited by 181
“coli Nissle 1917 [239], and Lactobacillus lactis [102] have been used as therapeutic vectors.”
Linking microbiota to human diseases: a systems biology perspective
Wu, H., Tremaroli, V., & Bäckhed, F. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.09.011 · Cited by 150
“For example, the administration of Escherichia coli Nissle 1917 synthesizing precursors of anorexigenic lipids reduced food intake and adiposity in mice fed a high-fat diet [112], while lactobacilli engineered to secrete full-length GLP-1 increased glucose tolerance in diabetic rats [113].”
BackgroundEmerging concepts in intestinal immune control of obesity-related metabolic disease
Khan, S., Luck, H., Winer, S., & Winer, D. A. (2021) · Nature Communications · doi:10.1038/s41467-021-22727-7 · Cited by 149
Yan, X., Liu, X.-Y., Zhang, D., Zhang, Y., Li, Z., Liu, X., Wu, F., & Chen, G. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00760-2 · Cited by 161
Self-citationProbiotics as Complementary Treatment for Metabolic Disorders
Le Barz, M., Anhê, F. F., Varin, T. V., Desjardins, Y., Levy, E., Roy, D., Urdaci, M. C., & Marette, A. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.4.291 · Cited by 142
Synthetic gene circuits for the detection, elimination and prevention of disease
Sedlmayer, F., Aubel, D., & Fussenegger, M. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0215-0 · Cited by 151
Tarantino, G., & Finelli, C. (2015) · Future Microbiology · doi:10.2217/fmb.15.13 · Cited by 125
Designer probiotics for the prevention and treatment of human diseases
Chua, K. J., Kwok, W. C., Aggarwal, N., Sun, T., & Chang, M. W. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.04.011 · Cited by 137
The gut microbiome in cardio-metabolic health
Hansen, T. H., Gøbel, R. J., Hansen, T., & Pedersen, O. (2015) · Genome Medicine · doi:10.1186/s13073-015-0157-z · Cited by 122
“[138] demonstrated that administering E.”
Yang, M. J., Qi, X., Li, N., Kaifi, J. T., Chen, S., Wheeler, A. A., Kimchi, E. T., Ericsson, A. C., Rector, R. S., Staveley-O’Carroll, K. F., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35861-1 · Cited by 142
Gut Microbiome and Response to Cardiovascular Drugs
Tuteja, S., & Ferguson, J. F. (2019) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.119.002314 · Cited by 134
Engineered bacteria as therapeutic agents
Piñero‐Lambea, C., Ruano‐Gallego, D., & Fernández, L. Á. (2015) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2015.05.004 · Cited by 123
Recent advances in microbial fermentation for dairy and health
Hill, D., Sugrue, I., Arendt, E., Hill, C., Stanton, C., & Ross, R. P. (2017) · F1000Research · doi:10.12688/f1000research.10896.1 · Cited by 108
Microbiota and Aging. A Review and Commentary
García‐Peña, C., Álvarez‐Cisneros, T., Quiroz‐Baez, R., & Friedland, R. P. (2017) · Archives of Medical Research · doi:10.1016/j.arcmed.2017.11.005 · Cited by 116
Designer Probiotics: Paving the Way to Living Therapeutics
Singh, B., Mal, G., & Marotta, F. (2017) · Trends in biotechnology · doi:10.1016/j.tibtech.2017.04.001 · Cited by 100
Oral delivery of bacteria: Basic principles and biomedical applications
Li, S., Jiang, W., Zheng, C., Shao, D., Liu, Y., Huang, S., Han, J., Ding, J., Tao, Y., & Li, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.011 · Cited by 97
Engineering Diagnostic and Therapeutic Gut Bacteria
Landry, B. P., & Tabor, J. J. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.bad-0020-2017 · Cited by 94
Microbial applications for sustainable space exploration beyond low Earth orbit
Koehle, A. P., Brumwell, S. L., Seto, E. P., Lynch, A. M., & Urbaniak, C. (2023) · npj Microgravity · doi:10.1038/s41526-023-00285-0 · Cited by 117
de Azúa, I. R., & Lutz, B. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2994-6 · Cited by 95
Next-Generation Probiotics and Chronic Diseases: A Review of Current Research and Future Directions
Tiwari, A. K., Krisnawati, D. I., Susilowati, E., Mutalik, C., & Kuo, T. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c08702 · Cited by 95
Nougayrède, J.-P., Chagneau, C. V., Motta, J.-P., Bossuet-Greif, N., Belloy, M., Taieb, F., Gratadoux, J.-J., Thomas, M., Langella, P., & Oswald, E. (2021) · mSphere · doi:10.1128/msphere.00624-21 · Cited by 82
“Engineered strains of Nissle 1917 have also been constructed to treat obesity through production of N- acylphosphatidylethanolamine (Chen et al., 2014) or to express a phenylalanine-metabolizing enzyme in response to the anoxic conditions in the gut, to treat phenylketonuria (Isabella et al., 2018).”
BackgroundHolmes, A., Finger, C. E., Morales‐Scheihing, D., Lee, J., & McCullough, L. D. (2020) · Translational research · doi:10.1016/j.trsl.2020.07.012 · Cited by 97
Roles for the gut microbiota in regulating neuronal feeding circuits
Yu, K. B., & Hsiao, E. Y. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143772 · Cited by 88
“Since then, the gut microbiota has been increasingly appreciated as regulating host metabolism (15–19) and appetite (11, 20), with translational implications for both obesity (6, 21–23) and eating disorders (24– 27).”
Multi-layer PLGA-pullulan-PLGA electrospun nanofibers for probiotic delivery
Ajalloueian, F., Guerra, P. R., Bahl, M. I., Torp, A. M., Hwu, E., Licht, T. R., & Boisen, A. (2021) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2021.107112 · Cited by 83
Kumar, M., Yadav, A. K., Verma, V., Singh, B., Mal, G., Nagpal, R., & Hemalatha, R. (2016) · Future Microbiology · doi:10.2217/fmb.16.4 · Cited by 78
The effect of oxidized phospholipids on phenotypic polarization and function of macrophages
Serbulea, V., DeWeese, D., & Leitinger, N. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.02.035 · Cited by 74
Role of the microbiota–gut–heart axis between bile acids and cardiovascular disease
Zhang, Z., Lv, T., Wang, X., Wu, M., Zhang, R., Yang, X., Fu, Y., & Liu, Z. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116567 · Cited by 88
Probiotics: Protecting Our Health from the Gut
Varela-Trinidad, G. U., Domínguez-Díaz, C., Solórzano-Castanedo, K., Íñiguez-Gutiérrez, L., Hernández-Flores, T. D. J., & Fafutis‐Morris, M. (2022) · Microorganisms · doi:10.3390/microorganisms10071428 · Cited by 84
Bacteria‐Based Materials for Stem Cell Engineering
Hay, J. J., Rodrigo‐Navarro, A., Petaroudi, M., Bryksin, A. V., García, A. J., Barker, T. H., Dalby, M. J., & Salmerón‐Sánchez, M. (2018) · Advanced Materials · doi:10.1002/adma.201804310 · Cited by 73
Emerging Frontiers in Microbiome Engineering
Inda, M. E., Broset, E., Lu, T. K., & de la Fuente‐Núñez, C. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.08.007 · Cited by 78
Gut microbiota and associated metabolites: key players in high-fat diet-induced chronic diseases
Du, W., Zou, Z., Ye, B., & Zhou, Y. Q. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2494703 · Cited by 91
“184,185 Additionally, modification of Lactobacillus to secrete GLP-1 and induce insulin secretion has shown improvement in hyperglycemia symptoms in diabetic rat models.”
Engineered butyrate-producing bacteria prevents high fat diet-induced obesity in mice
Bai, L., Gao, M., Cheng, X., Kang, G., Cao, X., & Huang, H. (2020) · Microbial Cell Factories · doi:10.1186/s12934-020-01350-z · Cited by 74
Defois, C., Ratel, J., Denis, S., Batut, B., Beugnot, R., Peyretaillade, É., Engel, E., & Peyret, P. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.01562 · Cited by 81
“…dysbiosis), such as IBD (Kostic et al., 2014) and extra-digestive disorders, which include metabolic syndromes (e.g., obesity, diabetes, etc.), autoimmune disorders and neurological disturbances (Vijay-Kumar et al., 2010; Chen et al., 2014; Mu et al., 2016; Teng et al., 2016; Vatanen et al., 2016).”
BackgroundHuss, P., Meger, A., Leander, M., Nishikawa, K., & Raman, S. (2021) · eLife · doi:10.7554/elife.63775 · Cited by 66
“As a result, they are promising tools for treatment of antibiotic-resistant bacterial infections and microbiome manipulation (Canfield and Duerkop, 2020; Chen et al., 2014; Clokie et al., 2011; Dedrick et al., 2019; Kilcher and Loessner, 2019; Kutter et al., 2015; Mizuno et al., 2020; Sausset et al., 2020; Schooley et…”
BackgroundFecal Microbiota Transplantation and Other Gut Microbiota Manipulation Strategies
Quaranta, G., Guarnaccia, A., Fancello, G., Agrillo, C., Iannarelli, F., Sanguinetti, M., & Masucci, L. (2022) · Microorganisms · doi:10.3390/microorganisms10122424 · Cited by 78
Targeted Approaches for In Situ Gut Microbiome Manipulation
Lee, H. L., Shen, H., Hwang, I. Y., Ling, H., Yew, W. S., Lee, Y. S., & Chang, M. W. (2018) · Genes · doi:10.3390/genes9070351 · Cited by 72
“For example, EcN was engineered to produce N-acylphosphatidylethanolamines, which are precursors to a family of anorexigenic lipids [57].”
BackgroundResultInfluentialGenetically Engineered Microorganisms and Their Impact on Human Health
Mahdizade Ari, M., Dadgar, L., Elahi, Z., Ghanavati, R., & Taheri, B. (2024) · International Journal of Clinical Practice · doi:10.1155/2024/6638269 · Cited by 67
“Diabetes, cardiovascular disease, and obesity induced by changes in lifestyle, consuming unhealthy foods, etc. are the most common metabolic disorders [179, 180].”
BackgroundInfluentialBriskey, D. R., Tucker, P. S., Johnson, D. W., & Coombes, J. S. (2016) · Clinical and Experimental Nephrology · doi:10.1007/s10157-016-1255-y · Cited by 75
“Alterations in the balance of intestinal microbiota (dysbiosis) have been shown to contribute to the pathogenesis of a range of diseases including obesity [32], liver disease [33] and insulin resistance [34].”
Biosensing in Smart Engineered Probiotics
Rottinghaus, A. G., Amrofell, M. B., & Moon, T. S. (2020) · Biotechnology Journal · doi:10.1002/biot.201900319 · Cited by 66
Probiotic delivery systems: a brief overview
Kim, J., Muhammad, N., Jhun, B. H., & Yoo, J. (2016) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-016-0259-7 · Cited by 67
“In recent years, probiotics have been extensively studied as a treatment option of various diseases such as obesity (Chen et al. 2014), diabetes (Lindsay 2015), cancer (Serban 2014), human immunodeficiency virus infection (Monachese et al. 2011), irritable bowel syndrome (Claes et al. 2010).”
BackgroundSynthetic Biology and the Gut Microbiome
Dou, J., & Bennett, M. R. (2017) · Biotechnology Journal · doi:10.1002/biot.201700159 · Cited by 63
“coli exhibit a decreased food intake and increased metabolic rate [27].”
Gut microbiome as a novel cardiovascular therapeutic target
Singh, V., Yeoh, B. S., & Vijay–Kumar, M. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.01.002 · Cited by 62
Synthetic Biology Approaches in the Development of Engineered Therapeutic Microbes
Kang, M., Choe, D., Kim, K., Cho, B., & Cho, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228744 · Cited by 64
Halmos, T., & Suba, I. (2015) · Orvosi Hetilap · doi:10.1556/650.2015.30296 · Cited by 63
Role of Postbiotics in Diabetes Mellitus: Current Knowledge and Future Perspectives
Cabello-Olmo, M., Araña, M., Urtasun, R., Encío, I., & Barajas, M. A. (2021) · Foods · doi:10.3390/foods10071590 · Cited by 68
The microbiome and gut endocannabinoid system in the regulation of stress responses and metabolism
Srivastava, R. K., Lutz, B., & Ruiz de Azua, I. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.867267 · Cited by 56
Ma, J., Li, C., Wang, J., & Gu, J. (2020) · Obesity · doi:10.1002/oby.22700 · Cited by 55
“Some modifications were made on the sequence of GLP-1 (7-37) to form a new GLP-1 GM (genetically modified) sequence (Patent Application Number 201811519742.”
BackgroundMethodWang, L., Cheng, X., Bai, L., Gao, M., Kang, G., Cao, X., & Huang, H. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01147-21 · Cited by 59
“observed to be excellent for improving intestinal metabolism (10, 11).”
BackgroundLayering genetic circuits to build a single cell, bacterial half adder
Wong, A., Wang, H., Poh, C. L., & Kitney, R. I. (2015) · BMC Biology · doi:10.1186/s12915-015-0146-0 · Cited by 50
“In contrast to the mammalian cell-based half 71 adder, which is developed mainly for therapeutic and biosensing applications, a prokaryotic half adder 72 can be used to enhance molecular process control and decision-making – for example in drug and 73 biofuel production, biosensing, bioremediation [21], and probiotic…”
MethodRuminococcaceae_UCG-013 Promotes Obesity Resistance in Mice
Feng, J., Ma, H., Huang, Y., Li, J., & Li, W. (2022) · Biomedicines · doi:10.3390/biomedicines10123272 · Cited by 55
Human microbiome restoration and safety
Daliri, E. B.-M., Tango, C. N., Lee, B. H., & Oh, D.-H. (2018) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2018.05.002 · Cited by 48
Probiotics in obstetrics and gynaecology
Griffin, C. (2015) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.12303 · Cited by 47
Gut Microbiota and Microbial Metabolism in Early Risk of Cardiometabolic Disease
Gabriel, C. L., & Ferguson, J. F. (2023) · Circulation Research · doi:10.1161/circresaha.123.322055 · Cited by 55
Lv, Q., Li, Z., Sui, A., Yang, X., Han, Y., & Yao, R. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.977187 · Cited by 59
“Nissle 1917 have been used for T1DM and T2DM therapy, which can offer an enormous advantage in improving insulin resistance and glucose homeostasis (Chen et al., 2014; Duan et al., 2015).”
MethodKatiraei, S., Anvar, S. Y., Hoving, L. R., Berbée, J. F. P., van Harmelen, V., & van Dijk, K. W. (2022) · Current Microbiology · doi:10.1007/s00284-022-02956-9 · Cited by 50
“We [4–6] and others [7, 8] have exploited possibilities to beneficially affect microbiota using probiotics or dietary compounds that affect the composition and/or activity of the gut bacteria.”
BackgroundEffendi, S. S. W., & Ng, I. (2022) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2022.2109405 · Cited by 50
“Meanwhile, other engineered EcN biotherapeutics works have been investigated in mice, including developing a drug for obesity, cancer, tumour, PKU, and hyperammonemia (Chen et al. 2014; Isabella et al. 2018; Zhang et al. 2018a; Kurtz et al. 2019; Leventhal et al. 2020; Chiang and Huang 2021).”
BackgroundRecent advances in metabolic and bariatric surgery
Albaugh, V. L., Flynn, C. R., Tamboli, R. A., & Abumrad, N. N. (2016) · F1000Research · doi:10.12688/f1000research.7240.1 · Cited by 57
Metadata
- Authors
- Chen, Z., Guo, L., Zhang, Y., L. Walzem, R., Pendergast, J. S., Printz, R. L., Morris, L. C., Matafonova, E., Stien, X., Kang, L., Coulon, D., McGuinness, O. P., Niswender, K. D., & Davies, S. S.
- Affiliations
- Vanderbilt University (US)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Davies, Sean S.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2014-06-24
- Volume
- 124
- Issue
- 8
- Pages
- 3391-3406
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4109548
- OpenAlex
- W2076877166
- Cited by
- 277
- References
- 76
- Citations by year
- 2026: 12 · 2025: 11 · 2024: 19 · 2023: 22 · 2022: 31 · 2021: 26 · 2020: 26 · 2019: 22 · 2018: 18 · 2017: 35 · 2016: 29 · 2015: 23 · 2014: 3
- FWCI
- 12.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- Funders
- National Institutes of Health (1dp2od003137-01, 5p60dk020593-31)
- National Institute of Diabetes and Digestive and Kidney Diseases (P60-DK020593, U24DK092993, DK59637, DK 20593, U24DK059637, P30DK058404, P30DK020593)
- National Center for Research Resources (UL1RR024975)
- National Center for Complementary and Integrative Health (R01AT007830, AT07830)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- obesity, gut microbiota, engineered bacteria, N-acylphosphatidylethanolamine, Escherichia coli Nissle 1917, high-fat diet, dietary intake, insulin resistance, hepatic steatosis, metabolic disorders, microbiome engineering
- MeSH terms
- Acyltransferases, Animals, Digestive System, Disease Models, Animal, DNA-Binding Proteins, Eating, Escherichia coli, Female, Humans, Liver, Male, Mice, Inbred C57BL, Obesity, Phosphatidylethanolamines, Recombinant Proteins, Weight Gain, Arabidopsis Proteins, Mice, Diet, High-Fat, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.